These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 17906076)

  • 1. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
    Tai YT; Dillon M; Song W; Leiba M; Li XF; Burger P; Lee AI; Podar K; Hideshima T; Rice AG; van Abbema A; Jesaitis L; Caras I; Law D; Weller E; Xie W; Richardson P; Munshi NC; Mathiot C; Avet-Loiseau H; Afar DE; Anderson KC
    Blood; 2008 Aug; 112(4):1329-37. PubMed ID: 17906076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
    Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
    Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
    van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
    Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
    Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
    J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
    Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
    Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
    Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
    Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
    Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
    Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
    Veillette A; Guo H
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):168-77. PubMed ID: 23731618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.
    Chu J; He S; Deng Y; Zhang J; Peng Y; Hughes T; Yi L; Kwon CH; Wang QE; Devine SM; He X; Bai XF; Hofmeister CC; Yu J
    Clin Cancer Res; 2014 Aug; 20(15):3989-4000. PubMed ID: 24677374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
    Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
    Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
    Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K; He X; Devine SM; Zhang X; Caligiuri MA; Hofmeister CC; Yu J
    Leukemia; 2014 Apr; 28(4):917-27. PubMed ID: 24067492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
    Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
    Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
    [No Abstract]   [Full Text] [Related]  

  • 14. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
    Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
    Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
    Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
    Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
    Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
    Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CS1-directed monoclonal antibody therapy for multiple myeloma.
    Benson DM; Byrd JC
    J Clin Oncol; 2012 Jun; 30(16):2013-5. PubMed ID: 22547601
    [No Abstract]   [Full Text] [Related]  

  • 18. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
    Asvadi P; Cuddihy A; Dunn RD; Jiang V; Wong MX; Jones DR; Khong T; Spencer A
    Br J Haematol; 2015 May; 169(3):333-43. PubMed ID: 25653020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
    Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
    Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
    Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
    Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.